The role of pharmacokinetic and pharmacodynamic studies in the planning of protocols for the treatment of childhood cancer

Cancer Treatment Reviews

Volumn 25, Issue 1, 1999, Pages 13-27

  Burke, G A A ^a   Estlin, E J ^a   Lowis, S P ^a  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

Author keywords

Childhood acute lymphoblastic leukaemia; Childhood cancer; Cytarabine; L asparaginase; Methotrexate; Pharmacodynamics; Pharmacokinetics; Phase I studies; Thiopurines

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; BODY SURFACE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG DISPOSITION; HUMAN; PHARMACODYNAMICS; REVIEW; SIDE EFFECT;

EID: 0033081807     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.1998.0098     Document Type: Review

References (89)

1. Sheiner LB, Grasela TH Jr. J Pharmacokin Biopharm. 19 (June suppl) 11S-24S, 1991 An introduction to mixed effect modeling: Concepts, definitions and justification.
2. Marsoni S Ungerleider R, Hurson S, Hammershaimb L. Tolerance to antineoplastic agents in children and adults. Cancer Treat Rep 1985; 69: 1263-1269
3. Balis F, Holcenberg J, Poplack D. General principles of chemotherapy in Pizzo P, Poplack D (eds) Principles and Practice of Pediatric Oncology (2nd Edition) JB Lippincott Co Philadelphia; 1993: 197-245
4. Smith M, Adamson P, Balis F, et al. Phase I and pharmacokinetic evalution of all-trans retinoic acid in pediatric patients. J Clin Oncol 1992; 10: 1666-1673
5. Boddy AV, Calvete JA, Olsen KB, Rafi I. Non-linear pharmacokinetics and metabolism of AG337, a rationally designed thymidylate synthase (TS) inhibitor. Br J Cancer 1995; 71 (suppl 24): 66
6. Rodman JH, Ambromowitch M, Sinkule JA, Hayes FA, Rivera GK, Evans WE. Clinical pharmacodynamics of continuous infusion teniposide: Systemic exposure as a determinant of response in a phase I trial. J Clin Oncol 1987; 5: 1007-1014
7. Newell DR, Pearson AD, Balmanno K, Price L, Wyllie RA, Keir M, Calvert AH, Lewis IJ, Pinkerton CR, Stevens MC. Carboplatin pharmacokinetics in children: The development of a paediatric dosing formula. J Clin Oncol 1993; 11: 2314-2323
8. Chessells JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK medical research council trial UKALL X. Medical research council working party on childhood leukaemia. Lancet 1995; 345(8943): 143-8
9. Veerman AJ, Hahlen K, Kamps WA, Vanleeuwen EF, de Vaan GA, Vanwering ER, Vanderdoes-Vandenberg A, Solbu G, Suciu S. Dutch childhood leukemia study group: Early results of study ALL VI (1984-1988). Hamatol Bluttransfus 1990; 33: 473-7
10. Balis F, Lester C, Chrousos G et al. Differences in cerebrospinal fluid penetration of corticosteroids: Possible relationship to the prevention of meningeal leukemia. J Clin Oncol 1987; 5: 202-207
11. Jones B, Freeman A, Shuster J et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Onc 1991; 19: 269-275
12. Lilleyman JS, French AJ, Young IP Variation in 17 oxogenic steroid excretion following oral prednisolone in children with lymphoblastic leukaemia. Oncology 1981; 38(5): 274-6
13. Choonara I, Wheeldon J, Rayner P, Blackburn M, Lewis I. Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 1989; 23(6): 392-4
14. Pieters R, Huismans DR, Loonen AH, Kählen K, van der Does-van den Berg A, van Wering ER, Veerman AJP. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 1991; 338: 399-403
15. Kaspers GJL, Veerman AJP, Pieters R, van Zantwijk CH, Smets LA, van Wering ER, van der Does-van den Berg A. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 997; 90(7): 2723-2729
16. Kaspers GJL, Veerman AJP, Popp-Snijders C, Lomecky M, van Zantwijk CH, Swinkels LMJW, van Wering ER, Pieters R. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Onc 1996; 27: 114-121
17. Levêque D, Jehl F, Monteil H. Vinblastine, vincristine and vinorelbine. In A Clinician's Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics Eds. Grochow LB and Ames MM. 1998 Williams and Wilkins. Baltimore. p 459-470.
18. Crom WR, de Graaf SSN, Synold T, Uges DRA, Bloemhof H, Rivera G, Christensen ML, Mahmoud H, Evans WE. Pharmacokinetics of vincristine in children and adolescents with acute lymphoblastic leukemia. J Pediatr 1994; 125: 642-9
19. de Graaf SSN, Bloemhof H, Vendrig DE, Uges DRA. Vincristine disposition in children with acute lymphoblastic leukaemia. Med Pediatr Oncol 1995; 24(4): 235-40
20. Chabner BA, Loo TL. Enzyme therapy: L-asparaginase. In Cancer Chemotherapy and Biotherapy Principles and Practice. Eds Chabner BA, Longo DL. Second Edition. Lippincott - Raven, Philidelphia. 1996, pp485-492
21. Ettinger LJ, Ettinger AG, Avramis VI, Gaynon PS. Acute lymphoblastic leukaemia: A guide to asparaginase and pegaspargase therapy. Biodrugs 1997; 7(1): 30-39
22. Eden OB, Shaw MP, Lilleyman JS, Richards S. Non-randomised study comparing toxicity of escherichia coli and erwinia asparaginase in children with leukaemia. Med Pediatr Onc 1990; 18: 497-502
23. Asselin BL, Within JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993; 11(9): 1780-1786
24. Dibenedetto SP, Di Cataldo A, Ragusa R, Meli C, Lo Nigro L. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from erwinia in children with acute lymphoblastic leukaemia. J Clin Onc 1995; 13(2): 339-344
25. Asselin BL, Ryan D, Frantz CN et al. In vitro and in vivo killing of acute leukemia cells by L-asparaginase. Cancer Res 1989; 49: 4363-4368
26. Boos J, Werber G, Ahlke E, Schulze-Westhoff P, Nowak-Gottl U, Wurthwein G, Verspohl EJ, Ritter J, Jurgens H. Monitoring of asparaginase activity and asparaginase levels in children on different asparaginase preparations. Eur J Cancer 1996; 32A(9): 1544-1550
27. Otten J, Suciu S, Lutz P, Benoit Y, Robert A, Thyss A, Plouvier E, Ferster A, Méchinaud F, Mazingue F, Brock P, Vilmer E, Solbu G, Waterkeyn C, Philippe N. The importance of L-asparaginase (A'Ase) in the treatment of Acute Lymphoblastic Leukaemia (ALL) in children: Results of the EORTC 58881 randomized phase III trial showing greater efficiency of Escherichia coli (E. coli) compared to Erwinia (Erw) A'Ase. Annual Congress of the Am. Soc. of Hematology Orlando, 6-10.12.96 abstr.2663
28. Allegra CJ. Antifolates. In: Cancer Chemotherapy: Principles and Practice. Chabner BA, Collins JM (eds). JB Lippincott Company, Philadelphia, 1996; pp 110-154, 1990
29. Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 1985a; 260: 9720-9726
30. Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosohribosylaminoimidazolecarboxymide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA 1985b; 82: 4881-4885
31. Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff VA. Temporary remissions in acute leukaemia in children produced by folic acid antagonist, 4-amoinoptroyl glutamic acid (aminopterin). New Engl J Med 1948; 238: 787-793
32. Pinkerton CR, Hardy JR. Cancer chemotherapy and mechanisms of resistance. In: Paediatric Oncology: Clinical Practice and Controversies, 2nd Edition. Pinkerton CR, Plowman PN (Eds), Chapman & Hall Medical, London, 1997: pp 159-188
33. Matherly LH, Taub JW. Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukaemia. Leukemia Lymphoma 1996; 21: 359-368
34. Pearson ADJ, Mills S, Amineddine HA, Long DR, Craft AW, Chessells JM. Pharmacokinetics or oral and intramuscular methotrexate in children with acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 1987; 20: 243-247
35. Craft AW, Rankin A, Aherne W. Methotrexate absorption in children with acute lymphoblastic leukaemia. Cancer Treat Rep 1980; S1: 65: 77-81
36. Pearson ADJ, Amineddine HA, Yule M, Mills S, Long DR, Craft AW, Chessells JM. The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia. Br J Cancer 1991; 64: 169-173
37. Camitta B, Levethal B, Lauer S, Adair S, Casper J, Civin C, Graham M, Mahoney D, Munoz L, Kiefer G, Kamen B. Intermediate-dose intravenous and mercaptopurine therapy for non-T, non-B acute lymphoblastic leukaemia of childhood J Clin Oncol 1989; 7: 1539-1544
38. Brecher ML, Weinberg V, Boyett JM, Sinks LF, Jones B, Glicksman A, Holland JF, Freeman AI. Intermediate dose methotrexate in childhood acute lymphoblastic leukaemia resulting in decreased incidence of testicular relapse. Cancer 1986; 58: 1024-1028
39. 2 in children with acute lymphoblastic leukaemia. Cancer 1987; 60: 5-13
40. Camitta B, Mahoney D, Lauer S, Shuster JJ, Adair S, Civin C, Munoz L, Steuber P, Strother D, Kamen B. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukaemia: A pediatric oncology group study. J Clin Oncol 1994; 12: 1383-389
41. Evans WE, Crom WR, Stewart CF, Bowman WP, Chen C-H, Abromowitch M, Simone JV. Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia. Lancet 1984; 1: 359-362
42. Evans WE, Crom W, Abromowitch M, Dodge R, Look T, Bowman WP, George SL, Pui CH. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukaemia. New Engl J Med 1986; 314: 471-477
43. Evans WE, Relling M, Rodman JH, Crom WR, Boyett JM, Pui C-H. Conventional compared with individualised chemotherapy for childhood acute lymphoblastic leukaemia. New Engl J Med 1998; 338: 499-505
44. Whitehead VM, Rosenblatt DS, Vuchich M-J, Shuster JJ, Witte A, Beaulieu D. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukaemia: A pilot prognostic factor analysis. Blood 1990; 76: 44-49
45. Goker E, Lin JT, Elisseyett Y, Tong WP, Niedzwiecki D, Tan C, Steinherz P, Schweitzer BI, Bertino JR. Decreased polyglutamation of methotrexate in acute lymphoblastic leukaemia blasts in adults compared to children with this disease. Leukaemia 1993; 7: 1000-1004
46. Whitehead VM, Vuchich MJ, Lauer SJ, Mahoney D, Carroll AJ, Schuster JJ, Esseltine DW, Payment C, Look AT, Akabutu J, Taylor LD, Camitta B, Pullen DJ. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (> 50 chromosomes) B-lineage acute lymphoblastic leukaemia: A pediatric oncology group study. Blood 1992; 80: 1316-1323
47. Barredo JC, Synold TW, Laver MV, Pui C-H, Priest DG, Evans WE. Differences in constitutive and post-methotrexate folylpolyglutamyl synthetase activity in B-lineage and T-lineage leukaemia. Blood 1994; 84: 564-569
48. Synold TW, Relling MV, Boyett JM, Rivera GK, Sandland JT, Mahmoud H, Crist WM, Pui C-H, Evans WE. Blast cell methotrexate-polyglutamate accumulation differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukaemia. J Clin Invest 1996; 94: 1996-2001
49. Masson E, Relling MV, Synold TW, Liu Q, Scheutz JD, Sandlund JT, Pui CH, Evans WE. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukaemic effects in vivo. J Clin Invest 1996; 97: 73-80
50. Wiley JS, Taupin J, Jamieson GP, Snook M, Sawyer WH, Finch LR. Cytosine arabinosaide transport and metabolism in acute leukaemias and T cell lymphoblastic lymphoma. J Clin Invest 1985; 75: 632-642
51. Chabner BA. Cytidine analogues. In Cancer Chemoerapy and Biotherapy. Edited by BA chabner and DL Longo. Lippincroft-Raven Publishers, Phiadelphia, 1996, pp 213-233
52. Kufe DW, Spriggs DR. Biochemical and cellular pharmacology of cytosine arabinoside. Semin Oncol 1985; 12: 34-48
53. Huang P, Robertson LE, Wright S, Plunkett W. High molecular weight DNA fragmentation: A critical event in nucleoside analogue-induced apoptosis in leukaemia cells. Clin Cancer Res 1995; 1: 1005-1013
54. Medical Research Council. Report to the council by the working party on leukaemia in childhood. Improvement in treatment for children with acute lymphoblastic leukaemia. The medical research council UKALL trials 1972-84. Lancet 1986; i: 408-411
55. Land VJ, Shuster JJ, Crist WM, Ravindranath Y, Harris MB, Krance RA, Pinkel D, Pullen DJ. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukaemia: A pediatric oncology group study. J Clin Oncol 1994; 12: 1939-1945
56. Harris RE, Sather HN, Feig SA. High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukaemia: The children's cancer group experience. Med Pediatr Oncol 1998; 30: 233-239
57. Slevin ML, Piall EM, Aherne GW, Johnston A, Lister TA. The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high-dose therapy. Med Pediatr Oncol 1982; 10 (suppl 1): 157-168
58. Avramis VI, Weinberg KI, Sato JK, Lenarsky C, Willoughby ML, Coates TD, Ozkaynak MF, Parkman R. Pharmacology studies of 1-b-D-arabinofuranosylcytosine in pediatric patients with leukaemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. Cancer Res 1989; 49: 241-247
59. Avramis VI, Biener R, Krailo M, Finklestein J, Ettinger L, Willoughby M, Siegel SE, Holcenberg JS. Biochemical pharmacology of high dose 1-b-D-arabinofuranosylcytosine in childhood acute leukaemia. Cancer Research 1987; 47: 6786-6792; Clin Cancer Res 1998; 4: 45-52
60. Avramis VI, Biener R, Krailo M, Finklestein J, Ettinger L, Willoughby M, Siegel SE, Holcenberg JS. Biochemical pharmacology of high dose 1-b-D-arabinofuranosylcytosine in childhood acute leukaemia. Cancer Research 1987; 47: 6786-6792; Clin Cancer Res 1998; 4: 45-52
61. Boos J, Hohenlochter B, Schulze-Westhoff P, Schiller M, Zimmermann M, Creutzig U, Ritter J, Jurgens H. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukaemia. Med Pediatr Oncol 1996; 26: 397-404
62. Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarajian H, Keating MJ. Saturation of 1-b-D-arabinofuranosylcytosine 5′-triphosphate accumulation in leukaemia cells during high-dose 1-b-D-arabinofuranosylcytosine therapy. Cancer Res 1987; 47: 3005-3011
63. Avramis VI, Wiersma S, Krailo MD, Ramilo-Torno V, Sharpe A, Liu-Mares W, Kwock R, Reaman GH, Sato JK. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/IL study in pediatric patients with relapsed leukemias. Clin Cancer Res 1998; 4: 45-52
64. McCarthy AJ, Pilcher LA, Hann IM Oakhill A. FLAG (Fludarabine, high dose cytarabine and G-CSF) for refractory and high risk relapsed acute leukaemia in children. Medical and Pediatric Oncology (In press)
65. Doroshow JH. Anthracycline and athracenediones. In Cancer Chemotherapy and Biotherapy. Principles and Practice. Eds. Chabner BA and Longo DL. 1996. Second Edition Lippicott-Raven. Philidelphia p409-434
66. von Hoff DD, Rozencweig M, Layard M, et al. Daunomycin-induced cardiotoxicity in children and adults. Am J Med 1977; 62: 200-208
67. Lipshultz SE, Colan SD, Gelber ED et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukaemia in children. N Engl J Med 1991; 324: 808-815
68. Sorensen K, Levitt G, Bull C, Chessells, Sullivan I. Anthracycline dose in childhood acute lymphoblastic leukaemia: Issues of early survival versus late cardiotoxicity. J Clin Oncol 1997; 15(1): 61-68
69. Pieters R, Hongo T, Loonen AH, Huismans DR, Broxterman HJ, Hählen K, Veerman AJP. Different types of non-P-glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukaemia. Br J Cancer 1992; 65: 691-697
70. Klumper E, Pieters R, den Boer ML, Huismans DR, Loonen AH, Veerman AJP. In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia. Br J Cancer 1995; 71: 1188-1193
71. D'Incalci M, Farina P, Sessa C, Mangioni C, Conter V, Masera G, Rocchetti M, Brambilla Pisoni M, Piazza E, Beer M, Cavalli F. Pharmacokinetics of VP16-213 given by different administration methods. Cancer Chemother Pharmacol 1982; 7: 141-145
72. Lowis SP, Newell DR. Etoposide for the treatment of paediatric tumours: What is the best way to give it? Eur J Cancer 1996; 32(14): 2291-2297
73. Rodman JH, Furman WL, Sunderland M, Rivera G, Evans WE. Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients. J Clin Oncol 1993; 11: 287-293
74. Slevin ML, Clark PI, Joel SP et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 1989; 7: 1333-1340
75. Lowis SP, Newell DR, Pearson ADJ. Exposure and schedule dependency of etoposide in neuroblastoma and leukaemia cells in vitro. Eur J Cancer 1995; 31(4): 622-626
76. Davidson A, Lewis I, Pearson ADJ, et al. 21-day schedule oral etoposide in children- a feasibility study. Eur J Cancer 1993; 29A: 2223-2225
77. McLeod H, Evans WE. Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins. Cancer Surveys 1993; 17: 253-268
78. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogenetic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-652
79. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336: 225-29
80. Hale JP, Lilleyman JS. Importance of 6-mercaptopurine dose in lymphoblastic leukaemia. Arch Dis Childhood 1991; 66: 462-466
81. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukaemia. J Clin Onc 1989; 17(12): 1816-1823
82. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 1994; 343: 1188-1190
83. Welch JC, Lilleyman JS. 6-mercaptopurine dose escalation and its effect on drug tolerance in childhood lymphoblastic leukaemia. Cancer Chemother Pharmacol 1996; 38: 113-116
84. Lennard L, Davies HA, Lilleyman JS. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer 1993; 68: 186-190
85. Kaijser GP, Beijnen JH. Oxazaphosphorines: Cyclophosphamide and ifosfamide. In A Clinician's Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics. Eds Grochow LB and Ames MM. 1998; p 229-258. Williams and Wilkins. Baltimore
86. Fernbach DJ, Griffith KM, Haggard ME, Holcomb TM, Sutow WW, Vietti TJ, Windmiller J. Chemotherapy of acute leukaemia in childhood. Comparison of cyclophosphamide and mercaptopurine. N Engl J Med 1966; 275: 451-456
87. Ayash LJ, Wright JE, Tretyakov O, Gonin R, Elias A, Wheeler C, Eder JP, Rosowsky A, Antman K, Frei E III. Cyclophosphamide pharmacokinetics: Correlation with cardiac toxicity and tumour response. J Clin Oncol 1992; 10: 995-1000
88. Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, Pearson ADJ, Idle JR. Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol 1996; 41: 13-19
89. Yule SM, Boddy AV, Cole M et al. Cyclophosphamide metabolism in children. Cancer Res 1995; 55(4): 803-9